Date of Award
2019
Document Type
Thesis
Degree Name
M.S. in Pharmaceutical Science
Department
Pharmacy Administration
First Advisor
Yi Yang
Second Advisor
Benjamin F. Banahan
Third Advisor
John P. Bentley
Relational Format
dissertation/thesis
Abstract
Results: The matched sample consisted of 4578 patients (2291 in each group). NOACs were found to significantly reduce the risk of stroke/SE compared to warfarin (Hazard Ratio (HR): 0.373, 95% confidence interval (CI): 0.247 - 0.564, p<0.001); but, no significant difference was seen between NOACs and warfarin in terms of reducing the risk of MI (HR: 0.864, CI: 0.594 – 1.257, p=0.446). NOACs were found to significantly reduce the risk of ICH (HR: 0.500, CI: 0.300 – 0.834, p=0.008) and OB (HR: 0.608, CI: 0.424 – 0.870, p=0.007); but no difference was seen in the risk of MGB (HR: 0.862, CI: 0.640 – 1.160, p=0.326) between NOACs and warfarin. NOACs were also found to reduce the risk of all-cause mortality (HR: 0.783, CI:0.656 – 0.873, p=0.007). The composite of effectiveness and safety outcomes, and all-cause mortality was statistically significant proving superior overall effectiveness and safety of NOAC therapy to warfarin therapy in terms of risk reduction (HR:0.685, CI:0.587 – 0.801, p<0.001).
Recommended Citation
Korgaonkar, Siddhi, "Comparative Effectiveness and Safety of Non-Vitamin K Antagonists Oral Anticoagulants and Warfarin in Elderly Patients with Non-Valvular Atrial Fibrillation and Diabetes" (2019). Electronic Theses and Dissertations. 1721.
https://egrove.olemiss.edu/etd/1721